TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections. TaBriX’s initial focus is on the treatment of drug-resistant TB.
The team has developed a series of first-in-class anti-TB drug candidates with a novel mode of action. When used in combination with current TB therapies, these candidates have the potential to:
- reduce multidrug-resistant infections
- increase efficacy of current antibiotics by 50%
- reduce treatment time and relapse
The biological processes targeted by TaBriX’s drug candidates are found in more than 50 other human microbial pathogens, including Non-Tuberculous Mycobacteria (NTM), which cause serious pulmonary infections on the rise worldwide.
TaBriX targets are also present in the priority list organisms of the World Health Organisation, responsible for drug-resistant infections.
The TaBriX team has demonstrated that their compounds have activity against drug-resistant TB and NTM infections, and are building on this validation to unlock the potential application to other microbial infections in large markets.
The TaBriX Company Mission
- Tackle the global threat of drug resistant TB
- Exploit a novel mode of action and therapeutic properties of our compounds as:
- Resistance breakers (effective on drug-resistance microbes)
- Antibiotic potentiators (increases efficacy of antibiotics)
- Improved pathology (reduction of inflammation, reduction of lesions)
- Build on the validation in TB to unlock the potential application to other microbial infections in wider markets
- Target vulnerable patient populations where the needs, and potential returns, are highest (diabetics, COPD, CF, immunosupressed, co-infected with HIV)